Literature DB >> 11557047

A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130.

C M Hilkens1, H Is'harc, B F Lillemeier, B Strobl, P A Bates, I Behrmann, I M Kerr.   

Abstract

The terminal portion of the Janus kinases (Jaks) contains a divergent FERM (Four-point-one, Ezrin, Radixin, Moesin) homology domain comprising 19 conserved hydrophobic regions. To determine the role of this domain in governing recruitment of Jak1, but not Jak3, to the gp130 subunit of the interleukin-6 family of cytokine receptors, the interaction of three Jak1/Jak3 chimeras with gp130 was investigated. Chimeras 1, 2 and 3 (Jak1 FERM regions 1-19, 1-18 and 1-8/Jak3, respectively) were all enzymically active. Chimeras 1 and 2 interacted with the cytoplasmic domain of gp130, although less efficiently than Jak1. Only chimera 2, however, restored gp130 signalling in Jak1-negative cells. The data are consistent with recruitment of Jak1 to gp130 through the Jak1 FERM domain, but also emphasise the likely requirement for precise Jak/receptor orientation to sustain function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557047     DOI: 10.1016/s0014-5793(01)02783-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  FERM domain interaction promotes FAK signaling.

Authors:  Jill M Dunty; Veronica Gabarra-Niecko; Michelle L King; Derek F J Ceccarelli; Michael J Eck; Michael D Schaller
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

2.  Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation.

Authors:  Jacqueline Sayyah; Kavitha Gnanasambandan; Sushama Kamarajugadda; Shigeharu Tsuda; Jennifer Caldwell-Busby; Peter P Sayeski
Journal:  Cell Signal       Date:  2011-06-29       Impact factor: 4.315

3.  Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.

Authors:  Megumi Funakoshi-Tago; Stephane Pelletier; Tadashi Matsuda; Evan Parganas; James N Ihle
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

4.  JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

Authors:  Maulik Patel; Sadakatsu Ikeda; Susan R Pilat; Razelle Kurzrock
Journal:  JAMA Dermatol       Date:  2017-05-01       Impact factor: 10.282

5.  Jak2 is a negative regulator of ubiquitin-dependent endocytosis of the growth hormone receptor.

Authors:  Joyce Putters; Ana C da Silva Almeida; Peter van Kerkhof; Agnes G S H van Rossum; Ana Gracanin; Ger J Strous
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

6.  Type-1 interferons contribute to oxygen glucose deprivation induced neuro-inflammation in BE(2)M17 human neuroblastoma cells.

Authors:  Myles Robert Minter; Moses Zhang; Robert Charles Ates; Juliet Marie Taylor; Peter John Crack
Journal:  J Neuroinflammation       Date:  2014-03-06       Impact factor: 8.322

Review 7.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

Review 8.  Deregulation of Interferon Signaling in Malignant Cells.

Authors:  Efstratios Katsoulidis; Surinder Kaur; Leonidas C Platanias
Journal:  Pharmaceuticals (Basel)       Date:  2010-02-04

9.  Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases.

Authors:  Man Liu; Chengqian Xiao; Mingwei Sun; Minjia Tan; Lihong Hu; Qiang Yu
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

10.  Classification of nonenzymatic homologues of protein kinases.

Authors:  K Anamika; K R Abhinandan; K Deshmukh; N Srinivasan
Journal:  Comp Funct Genomics       Date:  2009-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.